All In Biotech

Drug Trial Radar · NCT04941339

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

A Phase I, Open-label, Multi-center, First in Human, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of MRG002 in Patients With HER2 Positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

74

Planned (sponsor's estimate)

Start

Nov 21, 2018

Primary completion

Oct 2022

Study completion Oct 2022

Sponsor

Lead sponsor
Shanghai Miracogen Inc.Industry
Sponsor type
Industry
First posted
Jun 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • MRG002Drug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first treatment cycle (Day 1-28)
  2. Recommended Phase II Dose (RP2D)Time frame: Baseline to study completion (up to 6 months)
  3. Adverse Events (AEs)Time frame: Baseline to 49 days after the last dose of study treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Oriental Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.